Most patients with diffuse large B-cell lymphoma (DLBCL) patients achieve a long-term remission after first line treatment with combined immunotherapy and chemotherapy. Relapse can, however, sometimes occur after a period of DLBCL remission. Once a patient is in remission, the appropriateness of routine imaging (with CT or PET scans) for DLBCL patients is controversial and is believed by some to have limited value in detecting relapse. In a population based study published in the Journal of Clinical Oncology researchers from Denmark and Sweden compared the survival of different patients undergoing different types of routine imaging. In this video Dr. John Leonard explains the findings of this study in order to provide guidance in follow up monitoring strategies.
Previous #REDLAMP entries can be viewed on our Youtube channel.
We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.